Mathai Mammen, head of R&D for J&J’s Janssen unit (Rob Tannenbaum)

As J&J moves to split its busi­ness, ex­ecs lay out fu­ture R&D fo­cus — and tout megablock­buster po­ten­tial

Last week, J&J took a step fa­mil­iar to oth­er phar­ma con­glom­er­ates in spin­ning out its con­sumer busi­ness to fo­cus on R&D, but of­fered few de­tails on what that might look like. But on Thurs­day, the com­pa­ny fol­lowed up with the scoop, and it’s mak­ing some bold pre­dic­tions.

Over the course of a two-plus hour pre­sen­ta­tion on its phar­ma­ceu­ti­cal busi­ness, ex­ecs out­lined their strat­e­gy for the new, slim­mer J&J, promis­ing in­vestors it will file about 14 drugs for ap­proval through 2025. Across all these drugs, J&J said it ex­pects $4 bil­lion av­er­age peak an­nu­al sales, and five could top the $5 bil­lion mark.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA